NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

Over the last four quarters, the company has surpassed consensus EPS estimates four times. NovoCure, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $150.36 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 10.18%. This compares to year-ago revenues of $126.05 million. The company has topped consensus revenue estimates three times over the last four quarters. NovoCure shares have added about 25.9% since the beginning of the year ver ...